Rhythm Biosciences Ltd. (AU:RHY)

ASX:RHY

RHY

Rhythm Biosciences Ltd.

RESEARCH TOOLSreports

Want to see AU:RHY full AI Analyst Report?

Rhythm Biosciences Ltd. (RHY) Price & Analysis

12 Followers

RHY Stock Chart & Stats

AU$0.14

<AU$0.01(1.16%)

At close: Jan 09 4:00 PM EST

AU$0.14

<AU$0.01(1.16%)

Day’s Range― - ―

52-Week RangeAU$0.05 - AU$0.28

Previous CloseN/A

Volume786.78K

Average Volume (3M)462.98K

Market Cap

AU$63.71M

Enterprise ValueAU$60.55M

Total Cash (Recent Filing)AU$1.73M

Total Debt (Recent Filing)AU$262.44K

Price to Earnings (P/E)―

Beta0.93

Next Earnings

Aug 27, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)>-0.01

Shares Outstanding364,059,840

10 Day Avg. Volume510,821

30 Day Avg. Volume462,976

Financial Highlights & Ratios

PEG Ratio0.07

Price to Book (P/B)22.03

Price to Sales (P/S)4.56

P/FCF Ratio-4.94

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Focused CRC Blood-based ScreeningA narrowly focused product strategy targeting colorectal cancer screening creates a clear commercial path into population screening and clinical workflows. The device/assay plus algorithm approach can drive differentiated clinical utility, streamline adoption by providers, and enable licensing or distribution partnerships that scale over years.

High Gross Margin PotentialReported high gross margins imply attractive unit economics once tests are sold at scale. Durable gross-margin strength supports profitability as fixed R&D and go-to-market costs are absorbed, enabling sustainable operating leverage and stronger long-term cash generation when commercial traction is achieved.

Improving Free Cash Flow TrendAn improving free cash flow trend signals progress on cash management and nearer-term resilience. Persistently negative OCF remains a weakness, but improving FCF reduces future funding needs, strengthens negotiating leverage with partners, and increases the probability of reaching cash-neutral operations with scale.

Bears Say

Sharp Revenue DeclineA ~43% recent revenue drop indicates weak commercial traction or sales volatility, undermining scale economics and market credibility. For a diagnostics developer reliant on per-test revenue or service contracts, sustained revenue weakness impairs the ability to invest in market access, reimbursement efforts, and broader commercial rollout.

Persistent UnprofitabilityOngoing negative net, EBIT and EBITDA margins mean the company must continue to raise capital or secure non-dilutive partnerships to fund operations. Structural unprofitability constrains reinvestment in commercialisation and increases execution risk until regulatory approvals, reimbursement and steady test volumes convert margins positive.

Elevated Financial LeverageA D/E of ~1.68 signals significant leverage for a pre-commercial diagnostics firm, reducing financial flexibility. High debt raises interest and covenant risk, limits runway for commercialization delays, and increases the likelihood of dilutive equity raises or onerous financing terms if revenue or reimbursement timelines slip.

Rhythm Biosciences Ltd. News

Rhythm Biosciences Seeks ASX Quotation for New Options

Rhythm Biosciences Ltd. ( ($AU:RHY) ) has issued an update. Rhythm Biosciences has applied to the ASX for...

10d ago

RHY

Rhythm Biosciences Issues New Shares and Confirms Regulatory Compliance

An update from Rhythm Biosciences Ltd. ( ($AU:RHY) ) is now available. Rhythm Biosciences has issued 18,834,007 ordinary...

12d ago

RHY

Rhythm Biosciences Seeks ASX Quotation for 18.8 Million New Shares

The latest update is out from Rhythm Biosciences Ltd. ( ($AU:RHY) ). Rhythm Biosciences has applied to the...

12d ago

RHY

Rhythm Biosciences clarifies ASX query on underwriting agreement and disclosure gaps

An update from Rhythm Biosciences Ltd. ( ($AU:RHY) ) is now available. Rhythm Biosciences has responded to an...

13d ago

RHY

Rhythm Biosciences Raises $5.5m to Accelerate ColoSTAT and geneType Sales

Rhythm Biosciences Ltd. ( ($AU:RHY) ) has issued an update. Rhythm Biosciences has completed the successful exercise and...

13d ago

RHY

Rhythm Biosciences updates market on director’s lapsed unlisted options

The latest update is out from Rhythm Biosciences Ltd. ( ($AU:RHY) ). Rhythm Biosciences has reported a change...

20d ago

RHY

Rhythm Biosciences Plans Issue of 18.8 Million New Shares

Rhythm Biosciences Ltd. ( ($AU:RHY) ) has provided an update. Rhythm Biosciences has announced a proposed issue of...

25d ago

RHY

Rhythm Biosciences Seeks ASX Quotation for Nearly 2 Million New Shares

The latest announcement is out from Rhythm Biosciences Ltd. ( ($AU:RHY) ). Rhythm Biosciences Limited has applied for...

25d ago

RHY

Rhythm Biosciences Confirms RHYO Options Deadline and Underwriting Terms

Rhythm Biosciences Ltd. ( ($AU:RHY) ) has provided an announcement. Rhythm Biosciences has confirmed that the deadline for...

28d ago

RHY

Rhythm Biosciences Doubles ColoSTAT Test Network and Expands Clinician Access Program

Rhythm Biosciences Ltd. ( ($AU:RHY) ) just unveiled an announcement. Rhythm Biosciences has accelerated the commercial roll-out of...

29d ago

RHY

RHY FAQ

What was Rhythm Biosciences Ltd.’s price range in the past 12 months?

Rhythm Biosciences Ltd. lowest share price was AU$0.05 and its highest was AU$0.28 in the past 12 months.

What is Rhythm Biosciences Ltd.’s market cap?

Rhythm Biosciences Ltd.’s market cap is AU$63.71M.

When is Rhythm Biosciences Ltd.’s upcoming earnings report date?

Rhythm Biosciences Ltd.’s upcoming earnings report date is Aug 27, 2026 which is in 122 days.

How were Rhythm Biosciences Ltd.’s earnings last quarter?

Rhythm Biosciences Ltd. released its earnings results on Feb 18, 2026. The company reported -AU$0.007 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.007.

Is Rhythm Biosciences Ltd. overvalued?

According to Wall Street analysts Rhythm Biosciences Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Rhythm Biosciences Ltd. pay dividends?

Rhythm Biosciences Ltd. does not currently pay dividends.

What is Rhythm Biosciences Ltd.’s EPS estimate?

Rhythm Biosciences Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Rhythm Biosciences Ltd. have?

Rhythm Biosciences Ltd. has 364,059,840 shares outstanding.

What happened to Rhythm Biosciences Ltd.’s price movement after its last earnings report?

Rhythm Biosciences Ltd. reported an EPS of -AU$0.007 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.381%.

Which hedge fund is a major shareholder of Rhythm Biosciences Ltd.?

Currently, no hedge funds are holding shares in AU:RHY

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Rhythm Biosciences Ltd. Stock Smart Score

Neutral

Fundamentals

Return on Equity

-476.27%

Trailing 12-Months

Asset Growth

-47.76%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Rhythm Biosciences Ltd.

Rhythm Biosciences Limited, a transformative predictive cancer diagnostics technology company in Australia and internationally. The company engages in developing and commercializing medical diagnostics technology. It develops ColoSTAT, a blood test for the early detection of colorectal cancer. The company was incorporated in 2017 and is headquartered in Parkville, Australia.